What is Switch Therapeutics?
Switch Therapeutics is a pioneering biotechnology firm based in South San Francisco, California, dedicated to the development of biomarker-gated genetic medicines. The company operates at the intersection of advanced molecular biology and therapeutic innovation, focusing on precision medicine solutions that target disease at the genetic level. By utilizing biomarker-gated mechanisms, the company aims to enhance the specificity and efficacy of genetic interventions, thereby minimizing off-target effects and improving patient outcomes. This unique approach positions the company as a significant player in the evolving field of RNA modulation and gene therapy, where the ability to control therapeutic expression is paramount to success.
How much funding has Switch Therapeutics raised?
Switch Therapeutics has raised a total of $52M across 1 funding round:
Series A
$52M
Series A (2023): $52M with participation from BOLD Capital Partners, UCB Ventures, Upfront Ventures, Insight Partners, and Lilly
Key Investors in Switch Therapeutics
BOLD Capital Partners
BOLD Capital Partners is a venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world, focusing on emerging science that can disrupt large markets.
UCB Ventures
UCB Ventures is a strategic corporate venture fund focused on investing in early-stage companies that develop innovative therapeutic modalities, including cell and gene therapy.
Upfront Ventures
Upfront Ventures is a Los Angeles-based venture capital firm that supports technology-driven businesses seeking capital for growth and innovation across various sectors.
What's next for Switch Therapeutics?
Looking ahead, the strategic deployment of the $52M will likely focus on scaling the company's internal research capabilities and advancing its lead candidates through preclinical milestones. As the firm transitions from early-stage development to more mature operational phases, the focus will shift toward establishing robust clinical trial frameworks and expanding its intellectual property portfolio. The backing from high-profile investors provides not only the necessary financial runway but also access to a deep network of scientific and operational expertise. Future growth will be defined by the company's ability to validate its biomarker-gated platform in human trials, potentially setting a new standard for precision genetic medicine and attracting further strategic partnerships within the global biopharmaceutical ecosystem.
See full Switch Therapeutics company page
